BRIMONIDINE TARTRATE AND TIMOLOL MALEATE by Sentiss is components: brimonidine tartrate and timolol. Approved for elevated intraocular pressure (iop) in patients with glaucoma, ocular hypertension, replacement therapy due to inadequately controlled iop. First approved in 2022.
Drug data last refreshed 21h ago
components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher…
Worked on BRIMONIDINE TARTRATE AND TIMOLOL MALEATE at Sentiss? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.